Suchergebnisse - "Konecny, Gottfried E"

PubPharm (137)

1

A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer

enthalten in: Gynecologic oncology | 2024

von Cristea, M. | Stewart, D. | Synold, T. | +15

2

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

enthalten in: The New England journal of medicine | 2023

von Moore, K. | Angelergues, A. | Konecny, G. | +128

3

Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome : A surrogate marker of survival

enthalten in: Gynecologic oncology | 2023

von Marsh, L. | Kim, T. | Zhang, M. | +8

4

Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

enthalten in: Gynecologic oncology reports | 2023

von Hendershot, A. | Slabaugh, M. | Riaz, K. | +4

5

Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Wainberg, Z. | Singh, A. | Konecny, G. | +13

6

State of the Biomarker Science in Ovarian Cancer : A National Cancer Institute Clinical Trials Planning Meeting Report

enthalten in: JCO precision oncology | 2022

von Ethier, J. | Fuh, K. | Arend, R. | +6

7

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors

enthalten in: Diagnostic pathology | 2022

von Samiei, A. | Gjertson, D. | Memarzadeh, S. | +2

8

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors

enthalten in: Diagnostic pathology | 2022

von Samiei, A. | Gjertson, D. | Memarzadeh, S. | +2

9

NCCN Guidelines® Insights : Ovarian Cancer, Version 3.2022

enthalten in: Journal of the National Comprehensive Cancer Network : JNCCN | 2022

von Armstrong, D. | Alvarez, R. | Backes, F. | +35

10

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

enthalten in: Gynecologic oncology | 2022

von Hardesty, M. | Krivak, T. | Wright, G. | +11

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[14]